Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H23Cl2N3O3S |
| Molecular Weight | 468.397 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCS(=O)(=O)NC(=O)C1=CC2=C(C=C1)N=C(C)N2CC3=CC=C(Cl)C=C3Cl
InChI
InChIKey=UYGZODVVDUIDDQ-UHFFFAOYSA-N
InChI=1S/C21H23Cl2N3O3S/c1-3-4-5-10-30(28,29)25-21(27)15-7-9-19-20(11-15)26(14(2)24-19)13-16-6-8-17(22)12-18(16)23/h6-9,11-12H,3-5,10,13H2,1-2H3,(H,25,27)
| Molecular Formula | C21H23Cl2N3O3S |
| Molecular Weight | 468.397 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. | 2005 Dec |
|
| FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs. | 2005 Sep |
|
| Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat. | 2005 Sep 5 |
|
| A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties. | 2006 Aug |
|
| Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma. | 2006 Mar |
Patents
Sample Use Guides
FK-614, rosiglitazone, and pioglitazone competed for specific binding of [3H]rosiglitazone to peroxisome proliferator-activated receptor gamma (PPARgamma) with Ki values of 11 nM, 47 nM, and 1.3 microM, respectively. K614 induced interaction of PPARgamma with nuclear receptor coactivator CBP but of lower magnitude than rosiglitazone and pioglitazone. The estimated Kd values of FK614-, rosiglitazone-, and pioglitazone-PPARgamma complex to CBP peptide were 1.8, 0.64, and 0.72 microM, respectively, indicating FK-614/PPARgamma complex exhibits a lower affinity for CBP peptide compared to other agonist-PPARgamma complexes.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:38:50 GMT 2023
by
admin
on
Fri Dec 15 15:38:50 GMT 2023
|
| Record UNII |
V5Q32BZX79
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
V5Q32BZX79
Created by
admin on Fri Dec 15 15:38:50 GMT 2023 , Edited by admin on Fri Dec 15 15:38:50 GMT 2023
|
PRIMARY | |||
|
9869229
Created by
admin on Fri Dec 15 15:38:50 GMT 2023 , Edited by admin on Fri Dec 15 15:38:50 GMT 2023
|
PRIMARY | |||
|
DB12557
Created by
admin on Fri Dec 15 15:38:50 GMT 2023 , Edited by admin on Fri Dec 15 15:38:50 GMT 2023
|
PRIMARY | |||
|
DTXSID60940978
Created by
admin on Fri Dec 15 15:38:50 GMT 2023 , Edited by admin on Fri Dec 15 15:38:50 GMT 2023
|
PRIMARY | |||
|
193012-35-0
Created by
admin on Fri Dec 15 15:38:50 GMT 2023 , Edited by admin on Fri Dec 15 15:38:50 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
